Reata Pharmaceuticals, Inc. (NASDAQ:RETA) will hold its 3Q20 earnings conference call with the financial community on 9th November 2020 at 8:00 AM Eastern Time.
The conference call will be webcast live on Internet at www.reatapharma.com
Earnings Expectation
Reata Pharmaceuticals, Inc. is reporting third quarter financial results on Monday 9th November 2020, before market open.
According to analysts surveyed by Thomson Reuters, RETA is expected to report 3Q20 loss of $ 1.98 per share from revenue of $ 1.27 million.
For the full year, analysts anticipate top line of $ 6.96 million, while looking forward to loss of $ 7.84 per share bottom line.
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (Bard) for the treatment of patients with chronic kidney disease caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; and omaveloxolone that is Phase II clinical trial for the treatment of patients with Friedreichs ataxia It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of orphan neurological indications; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. Reata Pharmaceuticals, Inc.
